biote Corp. (NASDAQ:BTMD - Free Report) - Equities researchers at Roth Capital cut their FY2026 earnings per share estimates for biote in a report issued on Thursday, August 7th. Roth Capital analyst G. Kelly now anticipates that the company will post earnings of $0.44 per share for the year, down from their prior estimate of $0.70. The consensus estimate for biote's current full-year earnings is $0.75 per share.
biote (NASDAQ:BTMD - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.04. The business had revenue of $48.86 million for the quarter, compared to analyst estimates of $49.52 million. biote had a negative return on equity of 19.71% and a net margin of 15.73%.
A number of other research analysts have also weighed in on BTMD. B. Riley lowered biote from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $8.00 to $4.00 in a report on Thursday. Wall Street Zen lowered biote from a "strong-buy" rating to a "hold" rating in a report on Saturday.
Get Our Latest Report on biote
biote Trading Down 1.4%
NASDAQ:BTMD opened at $2.88 on Monday. The firm has a market cap of $157.56 million, a P/E ratio of 3.20 and a beta of 1.21. The stock's 50 day simple moving average is $4.00 and its 200-day simple moving average is $4.01. biote has a 12-month low of $2.87 and a 12-month high of $6.98.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of BTMD. CWM LLC grew its holdings in biote by 952.7% during the second quarter. CWM LLC now owns 8,674 shares of the company's stock worth $35,000 after acquiring an additional 7,850 shares during the period. Hsbc Holdings PLC purchased a new stake in biote during the first quarter worth $43,000. AQR Capital Management LLC purchased a new stake in biote during the first quarter worth $43,000. Virtu Financial LLC purchased a new stake in biote during the first quarter worth $62,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in biote during the second quarter worth $66,000. Institutional investors and hedge funds own 21.68% of the company's stock.
biote Company Profile
(
Get Free Report)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider biote, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.
While biote currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.